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Abstract: Estrogen receptor negative (ER(−)) breast cancer is aggressive, responds poorly 
to current treatments and has a poor prognosis. The NF-κB signaling pathway is implicated 
in ER(−) tumorigenesis. Aspirin (ASA) is chemopreventive against ER(+) but not for ER(−) 
breast cancers. Nitric oxide-releasing aspirin (NO-ASA) is a safer ASA where ASA is linked 
to an NO-releasing moiety through a spacer. In vitro, we investigated anti-proliferation 
effects of NO-ASA (para- and meta-isomers) against ER(−) breast cancer cells MDA-MB-231 
and SK-BR-23, effects on NF-κB signaling, and reactive oxygen species by standard 
techniques. In vivo, effects of NO-ASA were evaluated in a mouse xenograft model using 
MDA-MB-231 cells. p-NO-ASA inhibited the growth of MDA-MB-231 and SK-BR-3 cells 
at 24 h, the respective IC50s were 13 ± 2 and 17 ± 2 μM; ASA had an IC50 of >3000 μM in 
both cell lines. The IC50s for m-NO-ASA in MDA-MB-231 and SK-BR-3 were 173 ± 15 and 
185 ± 12 μM, respectively, therefore, implying p-NO-ASA as a stronger inhibitor of growth 
p-NO-ASA reduced cell growth by inhibiting proliferation, inducing apoptosis and causing 
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G0/G1 cell cycle block. Activation of NF-κB was inhibited by both isomers as demonstrated 
by decreases in NF-κB-DNA binding and luciferase activity at 24 h, However, m-NO-ASA 
produced transient effects at 3 h such as increased NF-κB-DNA-binding, increased levels of 
nuclear p50, even though both isomers inhibited IκB degradation. Increase in nuclear p50 by 
m-NO-ASA was associated with translocation of p50 in to the nucleus as observed by 
immunoflouresence at 3 h. NO-ASA induced reactive oxygen species (ROS) as evidenced 
by overall increases in both H2DCFDA (2′,7′-dichlorodihydrofluorescein) and DHE 
(dihydroethidium)-derived fluorescence. Inhibition of ROS by N-acetyl-cysteine reversed 
the m-NO-ASA-mediated translocation of p50 in to the nucleus. In xenografts, p-NO-ASA 
inhibited tumor growth by inhibiting proliferation (PCNA and tumor volume), inducing 
apoptosis (TUNEL positive cells) and reducing NF-κB expression. Both isomers inhibit cancer 
cells, inhibit NF-κB pathway and induce ROS, and have potential as anticancer compounds. 
Keywords: NSAIDs; NO-NSAIDs; NF-κB; oxidative stress; breast cancer; estrogen receptor 
 
1. Introduction 
Breast cancer is the second leading cause of cancer deaths in women in the US [1]. It is classified as 
either estrogen receptor positive (ER(+)) or estrogen receptor negative (ER(−)) [2]. The latter represent 
25%–30% of human breast cancers, are very aggressive and have a much poorer prognosis, given the 
lack of target-directed therapies. Due to the limitations of current therapies, chemoprevention emerges 
as a major component of breast cancer control. Selective estrogen receptor modulators such as tamoxifen 
and raloxifene have a well-established role in preventing breast cancer [3]. These agents, however, 
reduce the incidence of only ER(+) breast cancer [4] and can lead to the development of tamoxifen 
resistance [5], emphasizing the need to develop strategies for the chemoprevention of ER(−) breast cancer. 
Nitric oxide releasing nonsteroidal anti-inflammatory drugs (NO-NSAIDs) are a promising group of 
compounds for the control of cancer. They consist of a traditional NSAID and a covalently bound  
NO-releasing moiety (reviewed in [6,7]). The most promising of them is NO-aspirin (NO-ASA) (Figure 1). 
There is evidence that NO-ASA has a strong chemopreventive effect on colon and pancreatic cancer [8,9]. 
Furthermore, several animal and early human studies emphasize its apparent safety, at least when compared 
to conventional ASA [10,11]. 
A current approach to rational treatment development capitalizes on the knowledge of drug effects on cell 
signaling pathways relevant to cancer. Multiple lines of evidence implicate the NF-κB signaling pathway as 
playing an important role in mammary tumorigenesis. There are three sets of data which underscore the 
importance of NF-κB: First, activated NF-κB was detected predominantly in ER(−) vs. ER(+) breast tumors 
and mostly in ER(−) and ErbB2(+) tumors (86%) [12]. Second, activated NF-κB is associated with functional 
and biological significance; ER(−) breast cancer cells rely on NF-κB for aberrant cell proliferation  
and simultaneously avoid apoptosis [13]. Third, breast cancers that lack functional ER overexpress  
NF-κB-regulated genes [13]. Breast cancers often progress from a hormone-dependent, nonmetastatic, 
antiestrogen-sensitive phenotype to a hormone-independent, antiestrogen- and chemotherapy-resistant 
phenotype with highly invasive and metastatic growth properties. This progression is usually accompanied 
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by altered function of the ER or outgrowth of ER(−) cancer cells [13]. Indeed, the chemotherapeutic 
resistance in ER(−) breast cancers can be accounted for by the activation of NF-κB. The clear implication 
of these observations is that constitutively activate NF-κB is a bona fide target for ER(−) breast  
cancer [12,14]. 
Previous work by us as well as others, mainly in cell lines of leukemia, colon and pancreatic cancers, 
indicate that these compounds could affect the NF-κB pathway [15–17] and that reactive oxygen species 
(ROS) production contributed to the suppression of NF-κB activity in leukemic cells [17]. The NO donating 
compound NO-ASA induced ROS, which was associated with cell cycle arrest, anti-proliferative effects 
and apoptosis, as demonstrated mostly in colorectal and pancreatic cell lines [18–20]. Among the studies 
in breast cancer cells with NO donating compounds, encouraging effects and possible mechanisms of 
NO-ASA and two other compounds, NOSH-sulindac and NOSH-naproxen, in ER(+) cells have also 
been demonstrated [21,22]. However, regarding the aggressive ER(−) breast cancers, mechanistic 
studies of NO donating ASA or its isomers in this area are lacking and interplay of NF-κB pathway with 
ROS, if any, have not been examined in these cells. 
Regulating this pathway could prove useful for the primary or secondary prevention of ER(−) breast 
cancer. Therefore, we explored the effects of the para and meta isomers of NO-ASA using two ER(−) 
breast cancer cell lines and a xenograft model. In vitro, our results demonstrate that para and meta 
positional isomers of NO-ASA inhibit the growth of these two cell lines with the para isomer being more 
potent and that this effect is accompanied by inhibition of the NF-κB signaling and generation of ROS. 
The meta isomer of NO-ASA regulates NF-κB activity via ROS up-regulation, while the para isomer 
does not. In the xenograft model, p-NO-ASA reduced tumor volume, tumor mass and activated NF-κB. 
2. Results and Discussion 
2.1. NO-ASA Inhibits Breast Cancer Cell Growth 
The effect of two NO-donating derivatives, p- and m-NO-ASA, and the parent compound, ASA were 
examined on cell growth. Breast cancer cell lines SK-BR-3 and MDA-MB-231, which are ER(−), were 
exposed to various concentrations of these compounds for 24 h and MTT assays were performed.  
From their growth inhibition curves, Inhibitory Concentration (IC50) values were calculated (Table 1). 
p-NO-ASA was very potent in inhibiting the growth of both breast cancer cell lines; the IC50s being  
13 ± 2 and 17 ± 2 μM for MDA-MB-231 and SK-BR-3 cells, respectively. Compared to p-NO-ASA,  
m-NO-ASA was less potent, the corresponding IC50s being 173 ± 15 and 185 ± 12 μM for MDA-MB-231 
and SK-BR-3 cells, respectively. In this study an IC50 for ASA could not be determined even though 
concentrations as high as 3000 μM were used. This is consistent with other studies using colon and 
pancreatic cancer lines where concentrations as high as 5000 μM were used without reaching an IC50 for 
cell growth inhibition after 24 h of exposure [23]. Additionally, 48 h treatments were also performed 
and respective IC50s were determined (Table 1). For 48 h intervals, IC50s were lower compared to that 
for 24 h. For example, the IC50 for ASA, p-NO-ASA, m-NO-ASA in MDA-MB-231 cells at 48 h were  
2200 ± 180 μM, 3.3 ± 0.4 μM, 95 ± 10 μM, respectively; and in SK-BR-3 cells the corresponding values 
were 2550 ± 210, 5.3 ± 0.8 and 110 ± 15 μM. This implies there is a time dependent effect and biological 
activity in the medium of both compounds for up to 48 h. Compared with the parent ASA, the two  
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NO-donating derivatives showed many-fold increase in potency, as determined by the ratio of the IC50s. 
For example, the ratio of IC50 values (ASA/NO-ASA) for p-NO-ASA in MDA-MB-231 and SK-BR-3 
cells at 48 h were 667 and 481, indicating it to be 667-fold and 481-fold more potent than ASA. Similarly, 
m-NO-ASA was 23-fold more potent in both cell lines. For further analysis on cell growth, the triple 
negative cell line MDA-MB-231 was used. 
Table 1. IC50 values for ASA and NO-ASA, in MDA-MB-231 and SK BR 3 breast cancer cells. 
Drug 
IC50, μM, 24 h IC50, μM, 48 h 
MDA-MB-231 SK BR-3 MDA-MB-231 SK BR-3 
ASA >3000 † >3000 † 2200 ± 185 2550 ± 210 
p-NO-ASA 13 ± 2 * 17 ± 2 * 3.3 ± 0.4 5.3 ± 0.8 
m-NO-ASA 173 ± 15 * 185 ± 12 * 95 ± 10 110 ± 15 
Cells were treated with various concentrations of ASA, p-NO-ASA, and m-NO-ASA as described under 
Experimental Section. Cell numbers were determined by MTT at 24 and 48 h, from which IC50 values were 
calculated. Results are mean ± S.E.M. of at least three different experiments done in duplicate. *: p < 0.001 
compared to ASA. †: Exceeded the maximum concentrations used in these studies. 
2.2. NO-ASA Inhibits Cellular Proliferation, Alters Cell Cycle Phases and Induces Cell Death 
In order to evaluate the mechanism(s) involved in the reductions of cell growth, the effect of NO-ASA 
was evaluated on cell renewal and cell death, two determinants of cell growth. PCNA constitute a marker 
of proliferation status, thus MDA-MB-231 cells were analyzed for PCNA expression after treatment 
with p-NO-ASA for 24 h. The cells showed a significant antiproliferative effect, as seen by a 
concentration-dependent reduction in the expression of PCNA (Figure 1A). At 5 μM the reduction was 
81% ± 2% and at 15 μM it was 42% ± 5% (compared to control, p < 0.01). Qualitatively, similar results 
were obtained with m-NO-ASA but at higher concentrations implying lower potency (data not shown). 
Cell cycle transitions were examined by flow cytometry. Phases of the cell cycle were blocked by both 
NO-ASA positional isomers in MDA-MB-231 cells (Figure 1B). For example, following 24 h of 
treatment, p-NO-ASA induced a block of cells in the G0/G1 phase. This was evident by the increased 
population of cells in the G0/G1 phase that was accompanied by corresponding reductions of the 
proportion of cells in S and G2/M phases. 
Apoptosis was measured in the cells by Annexin V-FITC/PI assay followed by flow cytometry.  
Cells in early apoptosis were quantified by Annexin V-positive and PI-negative cell populations. At 24 h, 
m-NO-ASA 50 and 200 μM produced approximately 56% and 66% early apoptotic cells. At higher 
concentrations of 300 and 500 μM, these cells likely moved into late apoptosis as the Annexin V-positive 
and PI-negative populations were reduced to 55% and 39%, respectively. Similarly, 5 μM p-NO-ASA 
for 24 h produced large numbers of cells, approx. 61%, in early apoptosis, while 10 and 20 μM reduced 
this population to 50% and 35% respectively, possibly moving them to late apoptosis. Late apoptotic 
populations represented by Annexin V-positivity and PI- positivity increased accordingly (Figure 1C). 
Therefore, p-NO-ASA contributes its effects on cell growth by a combination of effects on proliferation, 
cell cycle arrest and apoptosis. It has been reported by us earlier through several studies that both isomers 
of NO-ASA also acts on these major cellular processes in various cell types. This agrees well with our 
current understanding that these effects of NO-ASA are independent of cell type [23]. 
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Figure 1. Effect of NO-ASA on MDA-MB-231 breast cancer cell kinetics. NO-ASA inhibits 
proliferation by altering cell cycle progression and inducing apoptosis. Cells were treated 
with vehicle, various concentrations of NO-ASA for 24 h and analyzed for (A) proliferation 
by PCNA antigen expression; (B) cell cycle phases by PI staining and flow cytometry;  
(C) cells were collected and analyzed for Annexin-V and PI labeling. The percentage of cells 
that were Annexin-V positive/PI negative (early apoptosis) and those that were Annexin-V 
positive/PI positive (late apoptosis) is shown as total apoptotic cells. In (A,C), results are 
mean ± SEM for three different experiments performed in duplicate, *: p < 0.05, compared to 
control. In (B), results are representative of two different experiments. This study was repeated 
twice generating results within 10% of those presented here. 
2.3. NO-ASA Inhibits NF-κB Signaling Pathway 
p-NO-ASA inhibits NF-κB-Luc reporter activity: Activation of the transcription factor NF-κB involves 
its translocation into the nucleus, where it binds to the appropriate DNA regulatory sequences. Normally, 
the DNA transportation domain of NF-κB is bound by IκB, thereby, sequestering the heterodimer in the 
cytoplasm. Hence, activation of NF-κB is regulated by the ubiqitination of IκB. NF-κB is constitutively 
expressed in most cancer cell lines and plays a major role in cell survival, specifically, proliferation and 
anti-apoptosis. First, we examined if NF-κB signaling is altered by p-NO-ASA. MDA-MB-231 cells were 
transfected with 4× κB-Luc reporter plasmid or the negative construct lacking the κB binding sequences. 
Post overnight incubation, transfected cells were treated with p-NO-ASA 0.1 to 30 κM for 18 h. p-NO-ASA 
reduced luciferase activity in a concentration dependent manner (Figure 2), and IC50 for this reduced 
transcriptional activity was 17 μM. 
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Figure 2. NO-ASA suppresses the NF-κB signal transduction pathway. MDA-MB-231 
breast cancer cells were transiently transfected with either the pNF-κB-Luc construct or with 
the control reporter plasmid, which lacks the κB binding sequences, as described in 
Experimental Section. After overnight incubation, transfected cells were treated with p-NO-ASA 
for 18 h. p-NO-ASA suppressed this signaling pathway with an IC50 of 17 ± 2 μM. Results 
are mean ± SEM for three different experiments, *: p < 0.05. 
2.4. NO-ASA Inhibits NF-κB DNA-Binding Activity 
We determined whether NO-ASA affects the NF-κB-DNA interaction in MDA-MB-231 cells by gel 
shift assays on nuclear extracts. Cells were treated for 3 or 24 h with p- or m-NO-ASA. Nuclear extracts 
were examined for binding to a P32-labeled 22-oligomer (probe) bearing the NF-κB binding sites.  
As shown in Figure 3, DNA-protein complexes representing NF-κB-bound probe were obtained with 
untreated extracts (Panel A, control, lane 2). Competition with the unlabeled probe as specific inhibitor 
caused ablation of the band (lane 3) while supershift with p65 and p50 antibodies confirmed that the  
NF-κB in the extract is the p65/p50 form (lanes 13 and 14). p-NO-ASA decreased the basal level of  
NF-κB bound DNA in a concentration- and a time-dependent manner. At 3 h, p-NO-ASA 20 μM strongly 
decreased DNA binding (Panel A, lane 8), while at 24 h, 10 μM and 20 μM were both effective (Panel B, 
lanes 7 and 8). In contrast, m-NO-ASA produced a biphasic effect; at 3 h there was increased DNA-binding 
at 200 and 400 μM (Panel A, lanes 10, 11) while at 24 h there was a sharp decrease at these concentrations 
(Panel B, lanes 11, 12). Finally, traditional ASA 1000 μM had no significant effect at any time point 
(Panel A, lane 12 and Panel B, lane 13). Therefore, we conclude that effects of NO-ASA involve both 
p50 and p65 subunits of NF-κB in MDA-MB-231 cells, and that reduced DNA binding results in reduced 
activation as observed in the reporter assay. 
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Figure 3. NO-ASA inhibits NF-κB-DNA binding. For this electrophoretic mobility shift 
assay (EMSA) of NF-κB activation, MDA-MB-231 cells were treated for 3 or 24 h with  
p-NO-ASA or m-NO-ASA or ASA. Panel A: MDA-MB-231 cells, treated for 3 h as follows. 
Lanes; 1: No extract; 2: control; 3: control + specific competitor; 4: control + nonspecific 
competitor; 5–8: p-NO-ASA, 1, 5, 10, and 20 μM, respectively; 9–11: m-NO-ASA, 50, 200, 
and 400 μM, respectively; 12: ASA, 1 mM; 13 and 14: supershift assay using p50 and p65 
antibodies, respectively. Panel B: MDA-MB-231 cells, treated for 24 h as follows. Lanes;  
1: No extract; 2: untreated extract; 3: control + specific competitor; 4: control + nonspecific 
competitor; 5–8: p-NO-ASA, 1, 5, 10, and 20 μM, respectively; 9: control; 10–12: m-NO-ASA, 
50, 200, and 400 μM, respectively; 13: ASA, 1 mM. 
2.5. Effect of NO-ASA on Protein Levels of NF-κB Subunit p50 
Nuclear extracts were examined for protein levels of p50 subunit of NF-κB in order to determine if 
translocation to nucleus is altered leading to reduced DNA-binding. Cells were treated with p-NO-ASA 
for 3 h, and protein extracts of nucleus and cytoplasm were obtained. Immunoblotting and normalization 
of p50 with nuclear Sam68 as internal control revealed reduced levels of p50 subunit in response to  
p-NO-ASA (Figure 4A and bar graphs). Therefore, p-NO-ASA inhibits nuclear translocation of p50, 
which agrees with the reporter assay results. It is well established that the inhibitory molecule IκBα binds 
to the NF-κB p50 and p65 subunits in the cytoplasm. Proteolytic degradation of this inhibitory subunit 
allows dissociation of binding and translocation of NF-κB subunits into the nucleus. We examined if 
reduced translocation of p50 into the nucleus by p-NO-ASA occurs by suppression of IκBα degradation. 
Cytoplasmic extracts showed p-NO-ASA increased amounts of IκBα implying inhibition of its degradation 
(Figure 4B and bar graphs). Therefore, p-NO-ASA inhibits IκBα degradation, leading to its continued 
binding to p50, and inhibiting p50 translocation to the nucleus. In contrast, m-NO-ASA also inhibits 
IκBα degradation, however it does not prevent translocation of p50 in the nucleus, rather it promotes 
translocation to the nucleus, which explains clearly the increased DNA-binding observed at 3 h  
(Figure 4A). At this time it is not yet clear how this increase in p50 occurs in the nucleus based on current 
understanding of NF-κB regulation. Other effects of m-NO-ASA on nuclear transport and/or nuclear 
pores may also need to be examined as a separate course of study to shed more light on this observation. 
It is well known that NF-κB regulates cell proliferation and cell death [24]. Our previous work has 
demonstrated that NO-ASA inhibits cell growth through its combined effects on cell proliferation and 
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apoptosis. The IC50 for cell growth inhibition and the IC50 for inhibition of NF-κB-DNA binding correlate 
well and imply a role of NF-κB in the dynamics of growth inhibition. The effects of NO-ASA on NF-κB 
pathway may be an important sole contributor. NF-κB is activated preferentially in many human breast 
cancers, for example constitutive NF-κB activation is shown to be preferentially involved in proliferation 
of basal-like subtype breast cancer cells [25]. 
 
Figure 4. NO-ASA affects NF-κB p50 and IκB levels. MDA-MB-231 cells were treated with 
indicated concentrations p- or m-NO-ASA. Immunodetection of protein levels was performed 
on (A) nuclear extracts for NF-κB p50 levels using SAM68 as internal control for nuclear 
proteins; and (B) cytoplasmic extracts for IκB levels, and β-Tubulin as internal loading control. 
Results are representative of two different experiments; bar graphs represents mean ± range 
of the two experiments. 
2.6. NO-ASA Induces ROS 
We examined whether NO-ASA induced ROS levels. H2DCFDA is a molecular probe that detects 
more than ten individual reactive species including peroxides [26,27]. DHE is a selective probe for 
superoxide anion (O2•−) [28]. Cells were treated with indicated concentrations of para and meta NO-ASA 
based on their IC50 values for growth inhibition for 1 h and analyzed for levels of intracellular peroxides 
as described in Experimental Section. Compared with control, 20 μM p-NO-ASA and 200 μM m-NO-ASA 
increased the population of cells representing DHE- and H2DCFDA-dependent fluorescence, indicating 
an induction of intracellular peroxides and superoxide anion O2•−, respectively (Figure 5A,B). ROS 
generation by IC50 levels of NO-ASA was almost twofold compared to the control cells and the para 
isomer produced less ROS than the meta isomer. 
We further performed microscopic evaluation in live cells to directly detect mitochondria-derived 
O2•− using MitoSOX Red. This study was performed with m-NO-ASA. MDA-MB-231 cells were treated 
with 200 μM m-NO-ASA for 3 h. Compared with untreated control, m-NO-ASA produced strong 
staining for ROS (or mitochondrial superoxide) in mitochondrion as visualized by MitoSox staining in 
live cells (Figure 5, Panels C–E). This indirectly implies that mitochondrial superoxide dismutase (SOD) 
responds to m-NO-ASA. As ROS induction maybe a compartment specific due to presence of different 
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types of SODs in cytoplasm and mitochondria [29] this opens up avenues for dissecting the pathways 
and enzymes involved. 
 
Figure 5. NO-ASA induces ROS levels. MDA-MB-231 cells were treated with NO-ASA 
for 1 h followed by staining with a general ROS probe DCFDA or DHE, which detects 
superoxide anions (Panel A). (A) Representative histogram for DCFDA is shown in (B). 
Values are the mean ± SEM of three independent experiments. *: p < 0.05 compared to 
untreated controls. NO-ASA also produces ROS in mitochondrion. MDA-MB-231 cells 
were treated with 200 μM m-NO-ASA for 3 h. Upper panel C represents vehicle-treated and 
the lower panel shows drug-treated cells. The red signal in panel C is MitoSox, which depict 
mitochondrial ROS. Panel D are unstained images. Panel E shows overlaid images from  
C and D. 
ROS are important signaling molecules [30]. Increase in oxidative stress appears to be an early event 
as ROS levels are induced at 1 h. The oxidative stress produced by ROS maybe a mechanism related to 
apoptosis induction in these cells, in particular because we found comparatively stronger apoptosis by 
both compounds as opposed to strong cell cycle alterations. However, in vivo studies showed NO-ASA 
spares the GI from the toxicity of the parent compound ASA [31,32]. Therefore, the fact that NO-ASA 
is GI sparing in vivo and yet induces ROS in vitro implies that the events are not mutually exclusive. 
This underscores the need for caution in translating in vitro data to in vivo observations. Similarly,  
NO-ASA induced the expression of COX-2 in various cell lines, whereas in animals it inhibited COX 
activity and expression of prostaglandins [15,32]. 
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Regarding NF-κB, very high ROS levels can push cells to apoptosis and overall production of huge 
oxidative stress and cell death has been reported associated with inhibition of the NF-κB signaling 
pathway [33]. Further, ROS can cause redox modifications that inhibit activation of NF-κB [34], therefore, 
NF-κB signaling and ROS may have reportedly associated roles in cell death mediated by NO-ASA. We 
investigated the relationship between increases in ROS and NO-ASA-mediated modulation of NF-κB in 
these cells and determined whether ROS is necessary for m-NO-ASA-mediated increases in nuclear  
NF-κB p50. For this, we inhibited ROS by a common ROS scavenger, N-acetyl cysteine (NAC). Cells 
were pretreated with NAC 10 mM followed by m-NO-ASA for 3 h, and immunofluorescence for p50 
was performed. m-NO-ASA (400 μM) increased p50 levels in the nucleus compared to control, as shown 
by an increase in signals in the nucleus (Figure 6 Panel A,) which was reduced substantially by NAC.  
In contrast, p-NO-ASA showed no detectable changes in p50 immunofluorescence at any concentration 
or with NAC compared to untreated control (data not shown) possibly because basal levels were low  
for detection by this method. Therefore, ROS is necessary for m-NO-ASA-mediated translocation of 
NF-κB p50 into the nucleus. Considering that more ROS was produced by m-NO-ASA than p-NO-ASA 
(Figure 5), it appears that ROS has a stronger role in modulating p50 by m-NO-ASA, and that overall 
cell growth inhibition by m-NO-ASA and p-NO-ASA may be attributed to differences in mechanisms. 
While generation of ROS is generally associated with higher NF-κB activity [35], inhibitory effect on 
NF-κB activation in lung epithelial cells is also known [36]. 
 
Figure 6. ROS is necessary for p50 translocation to nucleus by m-NO-ASA. MDA-MB-231 
cells were treated with m-NO-ASA for 3 h, immunofluorescence of p50 was performed using 
anti-p50 antibody or IgG control and a Two-Photon Laser Scanning Confocal Microscope. 
DAPI was used to stain the nucleus. Panel A, top to bottom. m-NO-ASA increased p50 levels 
in the nucleus compared to control, which was reduced substantially by NAC. Panel B, DAPI 
stained nucleus; and Panel C, merged. 
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2.7. NO-ASA Modulates Cell Proliferation and Inhibits NF-κB Activation in a ER(−) Xenograft Model 
To explore the relevance of our in vitro findings to breast cancer, we used a tumor xenograft model. In 
this prevention model, female athymic nude mice were pre-initiated by daily administration of p-NO-ASA 
(100 mg/kg, gavage) and a control group was gavaged with the vehicle for seven days, followed by 
subcutaneous implantation of MDA-MB-231 cells (3 × 106) in the right flank. Daily administration of 
the test agents continued to the end of the experiment. At the end of the study, p-NO-ASA-treated mice 
showed a considerable reduction in tumor volume compared with the control group (Figure 7). The mean 
tumor volumes at sacrifice for the control group and p-NO-ASA were 670 ± 40 mm3 and 210 ± 8 mm3, 
respectively. This is equivalent to a mean reduction of 68% (p < 0.05). 
 
Figure 7. Female athymic nude mice were divided into two groups (n = 10 per group).  
One group was gavaged daily with p-NO-ASA (100 mg/kg body weight) suspended in 
methylcellulose and the other group was gavaged with the vehicle. After one week of 
treatment, animals in both groups were implanted s.c. in the right flank with MDA-MB-231 
cells (3 × 106) suspended in 50% Matrigel. In the vehicle-treated animals, small tumors were 
palpable after one week. Tumor size was measured every four days, *: p < 0.05. 
Immunohistochemical staining of the tumors were performed for expression of NF-κB p65, PCNA 
and for apoptotic cells by TUNEL staining. Compared to control tumors, the treated group showed a 
strong reduction in expression of PCNA (from 26% ± 9% to 12% ± 2%) and increase in apoptotic cells 
(from 6% ± 2% to 15% ± 3%), respectively. NF-κB expression was also significantly reduced by p-NO-ASA 
(Figure 8). Therefore, p-NO-ASA suppressed tumor growth by a combination of increased apoptosis and 
reduced cell proliferation. 
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Figure 8. p-NO-ASA inhibits proliferation, induces apoptosis and decreases NF-κB p65 in vivo. 
Tumors were sectioned, probed, and scored as described in the Experimental Section. Average 
mitotic index at sacrifice was determined by PCNA, TUNEL and p65 staining (*: p < 0.05). 
Red arrows indicate apoptotic cells. Representative fields used for quantification are shown. 
3. Experimental Section 
3.1. Reagents 
The two positional isomers of NO-ASA, para isomer [2-(acetyloxy)benzoic acid 4-(nitrooxy 
methyl)phenyl ester]]; and the meta isomer [2-(acetyloxy)benzoic acid 3-(nitrooxy methyl)phenyl ester], 
were synthesized according to published methods [37]. ASA was obtained from Sigma (St Louis, MO, 
USA). Stock solutions (100 mM) were made in DMSO; final DMSO concentration was adjusted in all media 
to 1%. 
3.2. Breast Cancer Cells 
ER(−) breast cancer cell lines of two different subtypes were used in this study, MDA-MB-231 (ER−, 
PR−, HER2−, i.e., triple negative, basal-subtype, highly metastatic) and SK-BR-3 (ER−, PR−, HER2+ 
i.e., Her2 overexpression-subtype) were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA). All cells were grown per ATCC recommended instructions. 
3.3. Cell Growth Inhibition Assay 
The growth inhibitory effect of NO-ASA on breast cancer cells was measured using a colorimetric 
MTT assay kit (Roche). Briefly, cells were plated in 96-well plates at a density of 13.7 × 103 cells/well 
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and, following overnight incubation, p- or m-NO-ASA, or ASA, was added to the culture medium.  
At indicated time periods of treatment, viable cells were quantified with MTT substrate according to the 
manufacturer’s instructions. Growth inhibition is expressed as percentage of the corresponding control. 
3.4. Cell Proliferation 
Proliferating cell nuclear antigen (PCNA) was determined using an ELISA Kit (Calbiochem, La Jolla, 
CA, USA), in accordance with the manufacturers protocol and read on spectrophotometric plate reader. 
3.5. Flow Cytometry for Phase Distribution in the Cell Cycle and Detection of Apoptosis 
Cell Proliferation and Cell Cycle Phases: Cell Proliferation and Cell Cycle Analysis were performed 
as previously described [38]. Cell cycle phase distributions were obtained using a Coulter Profile XL 
equipped with a single argon ion laser. For each subset, we analyzed >10,000 events. All parameters were 
collected in listmode files. Data were analyzed on an XL Elite Work station (Coulter) using the Software 
programs Multigraph™ and Multicycle™. The percentage of cells in G0/G1, G2/M, and S phases was 
determined form DNA content histograms. 
3.6. Apoptosis Assay 
Cell death was FITC-labeled Annexin V and propidium iodide (PI), using an Annexin V-FITC apoptosis 
detection kit, (BD Biosciences, San Jose, CA, USA), according to the manufacturer’s instructions. 
Treated cells (floating and adherent cells) were collected, resuspended in an Annexin V binding buffer 
and transferred to test tubes containing FITC-labeled Annexin V and PI. The cells were then incubated 
for 15 min at room temperature in dark, and analyzed by flow cytometry. Annexin V-FITC-positive/ 
PI-negative cells were regarded as a measure of early apoptosis. In addition, qualitative determination 
of apoptosis was determined by fluorescence microscopy of cells stained with 4,6-diamidino-2-phenylindole 
(DAPI; Accurate Chemicals, Westbury, NY, USA). For each sample, at least five fields were examined. 
The morphological criteria used to identify apoptosis included cytoplasmic and nuclear shrinkage, 
chromatin condensation, and membrane blebbing. 
3.7. Cell Transfection and NF-κB Reporter Assays 
MDA-MB-231 breast cancer cells were transiently transfected with 800 ng of either the pNF-κB-Luc 
construct, which has 4× binding sites or the with the control reporter plasmid pTA-Luc construct representing 
the negative control (lacking the κB binding sequences) using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA, USA) transfection reagent. Cells were co-transfected with 400 ng β-gal construct to control for 
transfection efficiency. After overnight incubation, transfected cells were treated with NO-ASA for 18 h. 
Lysates were examined for luciferase activity (Promega, Madison, WI, USA) and normalized with  
β-galactosidase activity for transfection efficiency. 
3.8. Electrophoretic Mobility Shift Assays (EMSA) 
Briefly, cells were incubated with aspirin, p- or m-NO-Aspirin or solvent (DMSO) for the indicated 
times and concentrations. Nuclear extracts were prepared following standard protocols [39] and resuspension 
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of nuclear pellet in extraction buffer. Proteins obtained in the cellular lysis step were collected, stored 
and used in experiments requiring cytoplasmic lysates. Nuclear extracts were subjected to EMSA to 
evaluate NF-κB activation. The NF-κB DNA binding activity was assessed by reacting 20 μg of nuclear 
extract from control and treated cells with 33 nmol of a 32P-end-labeled 22-mer double-stranded NF-κB 
oligonucleotide (AGTTGAGGGGAC TTTCCCAGGC; Promega). The specificity of binding was tested 
by competition reactions, using a 50-fold excess of unlabeled NF-κB (specific) or AP-1 (nonspecific) 
consensus oligonucleotides. Supershift analysis was employed where extracts were incubated with 
antibodies against the NF-κB subunits p50 and p65 prior to the addition of probe. The complexes were 
separated on a 5% gel following standard protocols. 
3.9. Western Blotting 
Nuclear and cytoplasmic extracts as prepared as prepared above were examined for protein levels after 
they were fractionated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred onto 
nitrocellulose membranes. Immunodetection using antibodies against the NF-κBp50, IκBalpha, Sam68 or 
β-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was done for 1 h at room temperature  
or overnight at 4 °C. The membranes were developed by the enhanced chemiluminescence system 
(Amersham Biosciences, Piscataway, NJ, USA). 
3.10. Determination of Reactive Oxygen Species (ROS) 
MDA-MB 231 cells (0.3 × 106 cells/well) were plated in 6-well plates for 24 h after which they were 
treated with various concentrations of p-NO-ASA for 1 h. Cells were then trypsinized, washed once in 
PBS resuspended and then incubated for 30 min at 37 °C in the dark with the oxidation-sensitive 
fluorescent probes 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA, 10 μM) or dihydroethidium 
(DHE, 5 μM) (Molecular Probes, Life Technologies, NY, USA). Fluorescence intensity was then 
measured by flow cytometry using a FACS Calibur (BD Bioscience, San Jose, CA, USA). H2DCFDA 
is a probe for H2O2, peroxyl radical, including both alkylperoxyl and hydroperoxyl, while DHE is an 
intracellular probe that preferentially measures superoxide anion [40,41]. A minimum of 10,000 events 
were analyzed and expressed as fluorescent intensity vs. events. We also used the fluoroprobe MitoSOX 
Red which has a high sensitivity for superoxide detection within the mitochondria compared with the 
cytosol and therefore is used to directly and selectively to detect superoxide in the mitochondria of live 
cells by flourescence microscopy [41]. 
For immunofluorescence, cells were washed with phosphate-buffered saline and fixed with methanol 
at 20 °C for 10 min. Nuclei were premeabilized by treatment with 0.1% Triton X100/phosphate-buffered 
saline for 5 min. Cells were blocked in 2% BSA/phosphate-buffered saline for 15 min and incubated with 
rabbit p65, p50 or IgG control antibody (Santa Cruz/1:200) for 1 h at room temperature. Subsequently, 
cells were incubated with Alexa Fluor® 488 anti-rabbit secondary antibody for 1 h at 4 °C (1:2000). The 
Zeiss LSM 510 META NLO Two-Photon Laser Scanning Confocal Microscope System was used for 
detection of staining. 
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3.11. Xenografts 
Female athymic nude mice, 8-weeks-old, were divided into 2 groups (n = 10 per group). One group 
was gavaged daily with p-NO-ASA (100 mg/kg body weight) suspended in methylcellulose and the other 
group was gavaged with the vehicle. After one week of treatment, animals in both groups were implanted 
s.c. in the right flank with MDA-MB-231 cells (3 × 106) suspended in 50% Matrigel (BD Biosciences,  
San Jose, CA, USA). Both groups had free access to control diet AIN-76A (Research Diets, Inc.,  
New Brunswick, NJ, USA) and water. Mice were evaluated daily for signs of toxicity and were weighed 
weekly. In the untreated animals, small tumors were palpable after one week. Tumor size was measured 
every 4 days using electronic calipers, the tumor volumes were calculated using the following formula: 
length × width2/2. Thirty days post inoculation, the mice were sacrificed, the tumors excised and fixed 
in 10% buffered formalin for immunohistochemical studies. The animal protocol was approved by the 
Institutional Animal Care and Use Committee at Stony Brook University. 
3.12. Immunohistochemistry 
Paraffin embedded sections were dewaxed, rehydrated and microwave heated for 15 min in 0.01 M 
citrate acid buffer (pH 6.0) for antigen retrieval. Then, 3% hydrogen peroxide was applied to block 
endogenous peroxidase activity for 15 min and normal horse serum as blocking solution was incubated 
for 15 min. The primary antibody or isotype IgG control was applied and incubated overnight at 4 °C. 
Slides were washed 3 times with PBS, each for 5 min. The biotinylated secondary antibody and the 
streptavidin-biotin complex (Zymed Laboratories, South San Francisco, CA, USA) were applied, each 
for 30 min at room temperature with an interval washing. After rinsing with PBS, the slides were 
immersed for 5 min in the substrate 3,3′-diaminobenzidine (DAB, Sigma) 0.4 mg/mL with 0.003% 
hydrogen peroxide, then rinsed with distilled water, counterstained with hematoxylin, dehydrated and 
cover-slipped. Antibodies: PCNA 1:100, (Santa Cruz Biotechnology, Santa Cruz, CA, USA); NF-κB 
p65 (which recognizes activated NF-κB) 1:100, was from Chemicon International (Temecula, CA, USA). 
3.13. TUNEL Staining 
TUNEL staining was performed using the In Situ Cell Death Detection kit (Roche Applied Science, 
Indianapolis, IN, USA) following the manufacturer’s instructions. Briefly, 4 μm thick formalin-fixed, 
paraffin-embedded tissue sections were deparaffinized and rehydrated. Endogenous peroxidase activity 
was quenched by hydrogen peroxide and tissue protein was hydrolyzed with proteinase K (Roche Applied 
Science, Indianapolis, IN, USA). Negative control: sections incubated with Label Solution (without TdT 
enzyme). All other sections were incubated with TUNEL reaction mixture (fluorescein-labeled nucleotides) 
at 37 °C for 1 h in a humid chamber, incubated with Converter-POD solution (anti-fluorescein antibody 
conjugated with POD) for 30 min at 37 °C, treated with DAB and counterstained with hematoxylin. 
3.14. Scoring the Expression of Biomarkers 
For each animal and treatment group, 5 slides were prepared and scored by a pathologist blind to the 
identity of the specimens (400×). For PCNA, and TUNEL staining, cells with a brown nucleus were 
considered labeled and those with a blue nucleus unlabeled. For each, the percentage of positive cells 
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over the total cells counted was calculated. For NF-κB the following semi-quantitative scoring system 
was used. The extent of staining was graded as follows: 0 = no staining; 1+ = ≤25% of cells positive;  
2+ = 26%–50% of cells positive; and 3+ = ≥51% of cells positive. The intensity of staining was scored 
as follows: 0 = no staining; 1+ = faint; 2+ = moderate; 3+ = strong. 1+, 2+ and 3+ were recorded as 1, 2 
and 3 points, respectively. To compare differences in staining, an Expression index (EI) was calculated 
by the following formula: EI = Extent of staining × Intensity of staining, as described previously [9]. 
3.15. Statistics 
In vitro data are presented as means ± SEM for at least 3 different sets of plates and treatment groups. 
Xenograft data, tumor volume and mass are presented as means ± SEM for 10 animals in each group. 
Statistical comparison among the groups was performed using Student’s t-test. 
4. Conclusions 
Overall, these studies demonstrate that both isomers of NO-ASA have growth inhibitory effects  
that are associated with inhibition of the NF-κB pathway. NF-κB is known to be redox-sensitive and 
ROS production is likely to be a component of its regulation. A combination of these mechanisms has 
demonstrated potential anti-cancer activity in ER(−) breast cancer. In vivo effects have demonstrated 
strong benefit against ER(−) xenografts. 
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